AKT1 and cancer: Various agents inhibiting the PI3K/AKT/mTOR (PAM) pathway, such as rapamycin, are currently in various stages of clinical development in oncology, ranging from some in early phase evaluations to others that have already received regulatory approval for treatment in advanced cancers [94].